Pfizer begins external search for successor to Chief Scientific Officer Mikael Dolsten

PFIZER INC

CSO and President of R&D Mikael Dolsten to step down after over 15 years; external search launched.
Dr. Dolsten will stay in current role until successor is appointed, at least through Feb 28, 2025.
No successor named; transition process formally announced on July 9, 2024.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mikael Dolsten

Chief Scientific Officer and President, Pfizer Research & Development

PFE · PFIZER INC

Filed: July 10, 2024, 7:59 PM ET

On July 9, 2024, Pfizer Inc. (the "Company") announced that it is beginning the process of finding a successor for Dr. Mikael Dolsten, the Company’s Chief Scientific Officer and President, Pfizer Research & Development after his more than 15-year distinguished career with the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mikael Dolsten departed as Chief Scientific Officer and President, Pfizer Research & Development at PFIZER INC.

Role: Chief Scientific Officer and President, Pfizer Research & Development

Exact text from the filing

On July 9, 2024, Pfizer Inc. (the "Company") announced that it is beginning the process of finding a successor for Dr. Mikael Dolsten, the Company’s Chief Scientific Officer and President, Pfizer Research & Development after his more than 15-year distinguished career with the Company.

View on SEC.gov

PFIZER INC filing history →

Source: SEC EDGAR

accession 0000078003-24-000130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.